ZNRF3 Antibody (2035A) [Alexa Fluor® 532]

• Reactivity: Mu
• Applications: ICC/IF
• Clone: 2035A
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor 532

ZNRF3 Antibody (2035A) [Alexa Fluor® 532] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse ZNRF3
  Lys53-Met216
  Accession # Q5SSZ7
• Specificity: Detects mouse ZNRF3 in direct ELISAs.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for ZNRF3 Antibody (2035A) [Alexa Fluor® 532]

• BK747E2.3
• KIAA1133
• novel C3HC4 type Zinc finger (ring finger)
• RNF203
• zinc and ring finger 3
• zinc/RING finger protein 3
• ZNRF3

Background

ZNRF3 (Zinc/RING Finger protein 3) is a member of the ZNRF3 family of type 1 transmembrane ubiquitin ligases (1). Mature mouse ZNRF3 consists of a 163 amino acid (aa) extracellular domain (ECD) with a protease associated (PA) domain fold, a short transmembrane segment, and a 675 aa cytoplasmic tail that contains a RING-type zinc finger with E3 ubiquitin ligase activity. Within the ECD, mouse and human ZNRF3 share 98% sequence identity. ZNRF3 is co-expressed on the cell surface with the homologous protein RNF43. Both proteins serve to inhibit the Wnt signaling pathway through the ubiquitination of LRP6 and a majority of the Frizzled family of Wnt receptors (1, 4, 6). ZNRF3 ubiquitin ligase activity is regulated jointly by R-Spondin and its cell surface receptors, Lgr4, 5, and 6 (2). The R-Spondin-Lgr complex binds to and facilitates the removal of the ZNRF3 from the plasma membrane, resulting in an enhancement of Wnt signaling (3, 4). Conversely, ZNRF3 can antagonize R-Spondin enhanced Wnt signaling (3, 5). ZNRF3 is highly expressed in crypt stem cells of the intestine where it modulates Wnt-induced cell proliferation to control the turnover of intestinal epithelial cells (6). ZNRF3 expression is down-regulated in gastric carcinomas, and ZNRF3 mutations are linked to carcinomas of the gastric tract, pancreas, liver, and ovary (7-10).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.